Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Saeidinejad (Wigan, United Kingdom), S. Gnanalingam (Wigan, United Kingdom), A. Ashish (Wigan, United Kingdom). An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease. 4740

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27 Year: 2005 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 The efficacy of pirfenidone in scleroderma related interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Telemetric observation of the course and treatment effects of selected interstitial lung diseases associated with connective tissue diseases (CTD-ILD) – protocol presentation Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 A retrospective review to assess the effect of prednisolone and azathioprine on usual interstitial pneumonia disease progression Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease (CTD-ILD):a cross-sectional study and longitudinal study Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Choosing pharmacotherapy for ILD in patients with connective tissue disease Source: Breathe, 17 (4) 210114; 10.1183/20734735.0114-2021 Year: 2021 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016